Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.

Journal Article (Clinical Trial;Journal Article)

The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial. Four groups of participants (n = 20 per group) received nicotine plus mecamylamine, nicotine alone, mecamylamine alone, or no drug for 4 weeks before cessation. After the quit-smoking date, all subjects received nicotine plus mecamylamine treatment for 6 weeks. Nicotine skin patches (21 mg/24 hr) and mecamylamine capsules (2.5-5.0 mg twice per day) were used. Precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. Nicotine + mecamylamine reduced ad lib smoking, smoking satisfaction, and craving more than either drug alone. Moreover, the orthostatic decrease in blood pressure caused by mecamylamine was offset by nicotine. Mecamylamine before smoking cessation may be an effective adjunct to nicotine patch therapy.

Full Text

Duke Authors

Cited Authors

  • Rose, JE; Behm, FM; Westman, EC

Published Date

  • August 1998

Published In

Volume / Issue

  • 6 / 3

Start / End Page

  • 331 - 343

PubMed ID

  • 9725117

International Standard Serial Number (ISSN)

  • 1064-1297

Digital Object Identifier (DOI)

  • 10.1037//1064-1297.6.3.331


  • eng

Conference Location

  • United States